Distinct Pathological Pathways in Patients With Heart Failure and Diabetes - Université de Lorraine Access content directly
Journal Articles JACC: Heart Failure Year : 2020

Distinct Pathological Pathways in Patients With Heart Failure and Diabetes

Chim C Lang
  • Function : Author
Leong Ng
  • Function : Author


Objectives: The aims of this study were to compare the characteristics of patients with and without diabetes and to use network analyses to compare biomarker profiles and associated pathways in patients with diabetes compared with those without diabetes, which might offer new avenues for potential therapeutic targets. Background: Diabetes adversely affects clinical outcomes and complicates treatment in patients with heart failure (HF). A clear understanding of the pathophysiological processes associated with type 2 diabetes in HF is lacking. Methods: Network and pathway over-representation analyses were performed to identify unique pathological pathways in patients with and without diabetes using 92 biomarkers from different pathophysiological domains measured in plasma samples from 1,572 patients with HF (31% with diabetes) with reduced ejection fraction (left ventricular ejection fraction <40%). The results were validated in an independent cohort of 729 patients (30% with diabetes). Results: Biomarker profiles were first compared between patients with HF with and without diabetes. Patients with diabetes showed higher levels of galectin-4, growth differentiation factor 15, and fatty acid binding protein 4 and lower levels of paraoxonase 3. Network analyses were then performed, revealing that epidermal growth factor receptor and galectin-3 were the most prominent connecting proteins. Translation of these networks to biologic pathways revealed that diabetes was associated with inflammatory response and neutrophil degranulation. Diabetes conferred worse outcomes after correction for an established risk model (hazard ratio: 1.20; 95% confidence interval: 1.01 to 1.42). Conclusions: Concomitant diabetes in patients with HF with reduced ejection fraction is associated with distinct pathophysiological pathways related to inflammation, protein phosphorylation, and neutrophil degranulation. These data support the evaluation of anti-inflammatory therapeutic approaches, epidermal growth factor receptor in particular, for patients with HF and diabetes.
Fichier principal
Vignette du fichier
Manuscript.pdf (555.33 Ko) Télécharger le fichier
Supplementary material.pdf (465.98 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03757990 , version 1 (22-08-2022)




Jasper Tromp, Adriaan A Voors, Abhinav Sharma, João Pedro Ferreira, Wouter Ouwerkerk, et al.. Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. JACC: Heart Failure, 2020, 8 (3), pp.234-242. ⟨10.1016/j.jchf.2019.11.005⟩. ⟨hal-03757990⟩
25 View
40 Download



Gmail Mastodon Facebook X LinkedIn More